Home > Publications database > Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients > print

001     826699
005     20210129225655.0
024 7 _ |a 10.1080/15592294.2016.1229730
|2 doi
024 7 _ |a 1559-2294
|2 ISSN
024 7 _ |a 1559-2308
|2 ISSN
024 7 _ |a pmid:27623992
|2 pmid
024 7 _ |a WOS:000434326600002
|2 WOS
024 7 _ |a altmetric:12012888
|2 altmetric
024 7 _ |a 2128/22884
|2 Handle
037 _ _ |a FZJ-2017-00917
082 _ _ |a 610
100 1 _ |a Schlensog, Martin
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients
260 _ _ |a Austin, Tex.
|c 2018
|b Landes Bioscience
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1568798440_18953
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Secreted frizzled related protein 3 (SFRP3) contains a cysteine-rich domain (CRD) that shares homology with Frizzled CRD and regulates WNT signaling. Independent studies showed epigenetic silencing of SFRP3 in melanoma and hepatocellular carcinoma. Moreover, a tumor suppressive function of SFRP3 was shown in androgen-independent prostate and gastric cancer cells. The current study is the first to investigate SFRP3 expression and its potential clinical impact on non-small cell lung carcinoma (NSCLC). WNT signaling components present on NSCLC subtypes were preliminary elucidated by expression data of The Cancer Genome Atlas (TCGA). We identified a distinct expression signature of relevant WNT signaling components that differ between adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Of interest, canonical WNT signaling is predominant in LUAD samples and non-canonical WNT signaling is predominant in LUSC. In line, high SFRP3 expression resulted in beneficial clinical outcome for LUAD but not for LUSC patients. Furthermore, SFRP3 mRNA expression was significantly decreased in NSCLC tissue compared to normal lung samples. TCGA data verified the reduction of SFRP3 in LUAD and LUSC patients. Moreover, DNA hypermethylation of SFRP3 was evaluated in the TCGA methylation dataset resulting in epigenetic inactivation of SFRP3 expression in LUAD, but not in LUSC, and was validated by pyrosequencing of our NSCLC tissue cohort and in vitro demethylation experiments. Immunohistochemistry confirmed SFRP3 protein downregulation in primary NSCLC and indicated ...
536 _ _ |a 552 - Engineering Cell Function (POF3-552)
|0 G:(DE-HGF)POF3-552
|c POF3-552
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Magnus, Lara
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Heide, Timon
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Eschenbruch, Julian
|0 P:(DE-Juel1)174333
|b 3
700 1 _ |a Steib, Florian
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Tator, Maximilian
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Kloten, Vera
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Rose, Michael
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Noetzel, Erik
|0 P:(DE-Juel1)145698
|b 8
700 1 _ |a Gaisa, Nadine T.
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Knüchel, Ruth
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Dahl, Edgar
|0 P:(DE-HGF)0
|b 11
|e Corresponding author
773 _ _ |a 10.1080/15592294.2016.1229730
|g p. 00 - 00
|0 PERI:(DE-600)2248598-3
|n 3
|p 214-227
|t Epigenetics
|v 13
|y 2018
|x 1559-2308
856 4 _ |u https://juser.fz-juelich.de/record/826699/files/Schlensog%20et%20al.%20-%202018%20-%20Epigenetic%20loss%20of%20putative%20tumor%20suppressor%20S.._.pdf
|y Restricted
856 4 _ |x pdfa
|u https://juser.fz-juelich.de/record/826699/files/Schlensog%20et%20al.%20-%202018%20-%20Epigenetic%20loss%20of%20putative%20tumor%20suppressor%20S.._.pdf?subformat=pdfa
|y Restricted
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/826699/files/Schlensog%20et%20al.%20-%202016%20-%20Epigenetic%20loss%20of%20putative%20tumor%20suppressor%20i.._.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/826699/files/Schlensog%20et%20al.%20-%202016%20-%20Epigenetic%20loss%20of%20putative%20tumor%20suppressor%20i.._.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:826699
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)174333
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 8
|6 P:(DE-Juel1)145698
913 1 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-552
|2 G:(DE-HGF)POF3-500
|v Engineering Cell Function
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2018
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EPIGENETICS-US : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-7-20110106
|k ICS-7
|l Biomechanik
|x 0
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)ICS-7-20110106
981 _ _ |a I:(DE-Juel1)IBI-2-20200312

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21